Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Improvement of HbA(1c) without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin
Autore:
Quattrin, T; Thrailkill, K; Baker, L; Kuntze, J; Compton, P; Martha, P;
Indirizzi:
SUNY Buffalo, Childrens Hosp Buffalo, Ctr Diabet, Buffalo, NY 14222 USA SUNY Buffalo Buffalo NY USA 14222 falo, Ctr Diabet, Buffalo, NY 14222 USA Univ Kentucky, Dept Pediat, Lexington, KY USA Univ Kentucky Lexington KY USA Kentucky, Dept Pediat, Lexington, KY USA Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA Childrens Hosp Philadelphia Philadelphia PA USA 19104 lphia, PA 19104 USA Genentech Inc, S San Francisco, CA 94080 USA Genentech Inc S San Francisco CA USA 94080 S San Francisco, CA 94080 USA
Titolo Testata:
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
fascicolo: 3, volume: 14, anno: 2001,
pagine: 267 - 277
SICI:
0334-018X(200103)14:3<267:IOHWIH>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
FACTOR-BINDING PROTEIN-1; GLYCEMIC CONTROL; RETINOPATHY; HORMONE; THERAPY; SENSITIVITY; SOMATOMEDIN; RESISTANCE; SYSTEM;
Keywords:
rhIGF-I therapy; IGF binding proteins; insulin; insulin resistance; HbA(1c); metabolic control; type 1 diabetes mellitus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Quattrin, T SUNY Buffalo, Childrens Hosp Buffalo, Ctr Diabet, 219 Bryant St, Buffalo, NY 14222 USA SUNY Buffalo 219 Bryant St Buffalo NY USA 14222 , NY 14222 USA
Citazione:
T. Quattrin et al., "Improvement of HbA(1c) without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin", J PED END M, 14(3), 2001, pp. 267-277

Abstract

Objective: A 12-week trial with insulin and rhIGF-I compared to insulin and placebo was conducted in patients with type 1 diabetes mellitus aged 11-66 years. We present the efficacy and safety data pertinent to the younger subset of participants (11-21 years). Study design: The patients were randomized to receive s.c. insulin and either placebo or rhIGF-I at one of the following doses (mug/kg): 40 a.m./40 p.m., 80 a.m./40 p.m. or 80 a.m./60 p.m.). Results: The average decrease of HbA(1c) from baseline was higher (-1.3 +/- 0.2%) in the rhIGF-I treated group compared to the placebo group (-0.6 +/- 0.3%; p < 0.05). This was associated with a significant decrease in dailyinsulin dose (U) of both Regular (rhIGF-I: -7 +/- 1; placebo: -1 +/- 1; p < 0.01) and NPH (rhIGF-I: -4 +/- 2; placebo: +5 rt 3; p < 0.05). The incidence of hypoglycemia and weight gain were not increased. Edema, jaw pain andtachycardia were associated with rhIGF-I treatment, particularly at doses higher than 40 <mu>g/kg b.i.d. Dose-related early worsening of retinopathy was observed in 11/55 patients in the rhIGP-I group, with resolution in themajority of them in the follow-up photographs. Conclusions: These findings suggest a possible role for rhIGF-I co-therapyin adolescents and young adults with type 1 diabetes mellitus.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:55:21